Tg Therapeutics (TGTX) FCF Margin (2017 - 2026)

Tg Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 8.76% for Q1 2026.

• In Q1 2026, FCF Margin rose 1502.0% year-over-year to 8.76%; the TTM figure through Mar 2026 stood at 2.03% (up 1379.0% YoY), while the FY2025 annual figure was 4.05%, up 827.0% from the prior year.
• FCF Margin for Q1 2026 stood at 8.76%, down from 10.17% in the prior quarter.
• The five-year high for FCF Margin was 50.48% in Q3 2023, with the low at 36701.06% in Q3 2022.
• The 5-year median for FCF Margin is 23.72% (2024), against an average of 4664.84%.
• The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 3338678 bps in 2022, then jumped 3675154 bps in 2023.
• Tg Therapeutics' FCF Margin stood at 29841.25% in 2022, then surged by 100 bps to 30.04% in 2023, then increased by 21 bps to 23.72% in 2024, then soared by 143 bps to 10.17% in 2025, then plunged by 186 bps to 8.76% in 2026.
• Business Quant data shows TGTX's FCF Margin at 8.76% in Q1 2026, 10.17% in Q4 2025, and 14.37% in Q3 2025.